FDA Approves Product Under Rare Pediatric Disease Priority Review Voucher

Summary

The FDA has approved a product, ULTOMIRIS (ravulizumab-cwvz), redeeming a priority review voucher for a rare pediatric disease, following the issuance of a notice by the agency.